Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disorders of obesity are diagnosed and treated.

Disorders of severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key pathway responsible for regulating weight, that lead to excessive or insatiable hunger or hyperphagia. Rhythm’s MC4R agonist, setmelanotide, is being evaluated in multiple late-stage clinical studies. The company is also leading efforts to improve patient identification and diagnosis through genetic testing and deepen the community’s understanding of the ongoing impact and burden of disease on patients and caregivers.